H5P Stock Overview
Develops, manufactures, markets, and sells a range of generic, branded, and in-licensed pharmaceutical products. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 1/6 |
| Past Performance | 3/6 |
| Financial Health | 4/6 |
| Dividends | 5/6 |
Community vs My Fair Value
Create NarrativeSelect a narrative for quick price alerts from the community, or create your own.
My Notes
Capture your thoughts, links and company narrative
Hikma Pharmaceuticals PLC Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | UK£27.80 |
| 52 Week High | UK£28.40 |
| 52 Week Low | UK£20.60 |
| Beta | 0.45 |
| 1 Month Change | 8.59% |
| 3 Month Change | 17.80% |
| 1 Year Change | 13.93% |
| 3 Year Change | 18.80% |
| 5 Year Change | 30.82% |
| Change since IPO | 583.05% |
Recent News & Updates
Recent updates
Shareholder Returns
| H5P | DE Pharmaceuticals | DE Market | |
|---|---|---|---|
| 7D | 1.5% | 0.6% | -0.6% |
| 1Y | 13.9% | -16.8% | 14.8% |
Return vs Industry: H5P exceeded the German Pharmaceuticals industry which returned -16.8% over the past year.
Return vs Market: H5P matched the German Market which returned 14.8% over the past year.
Price Volatility
| H5P volatility | |
|---|---|
| H5P Average Weekly Movement | 2.7% |
| Pharmaceuticals Industry Average Movement | 4.1% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 11.5% |
| 10% least volatile stocks in DE Market | 2.6% |
Stable Share Price: H5P has not had significant price volatility in the past 3 months compared to the German market.
Volatility Over Time: H5P's weekly volatility (3%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1978 | 9,100 | Riad Mishlawi | www.hikma.com |
Hikma Pharmaceuticals PLC develops, manufactures, markets, and sells a range of generic, branded, and in-licensed pharmaceutical products. It operates through three segments: Injectables, Generics, and Branded. The Injectables segment provides generic injectable products primarily for use in hospitals.
Hikma Pharmaceuticals PLC Fundamentals Summary
| H5P fundamental statistics | |
|---|---|
| Market cap | €6.18b |
| Earnings (TTM) | €272.43m |
| Revenue (TTM) | €2.88b |
22.7x
P/E Ratio2.1x
P/S RatioIs H5P overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| H5P income statement (TTM) | |
|---|---|
| Revenue | US$3.02b |
| Cost of Revenue | US$1.57b |
| Gross Profit | US$1.45b |
| Other Expenses | US$1.16b |
| Earnings | US$285.00m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
Feb 26, 2025
| Earnings per share (EPS) | 1.29 |
| Gross Margin | 47.99% |
| Net Profit Margin | 9.45% |
| Debt/Equity Ratio | 53.2% |
How did H5P perform over the long term?
See historical performance and comparisonDividends
2.7%
Current Dividend Yield61%
Payout RatioCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/02/22 10:07 |
| End of Day Share Price | 2025/02/21 00:00 |
| Earnings | 2024/06/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Hikma Pharmaceuticals PLC is covered by 37 analysts. 8 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Kamla Singh | AlphaValue |
| Simon Mather | Barclays |
| Emily Field | Barclays |